Format

Send to

Choose Destination
Front Oncol. 2015 Jan 15;4:385. doi: 10.3389/fonc.2014.00385. eCollection 2014.

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.

Author information

1
Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center , New York, NY , USA ; Weill Cornell Medical College , New York, NY , USA.
2
Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center , New York, NY , USA ; Weill Cornell Medical College , New York, NY , USA ; Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center , New York, NY , USA.

Abstract

Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations.

KEYWORDS:

CLTA-4; PD-1; immunotherapy; ipilimumab; nivolumab

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center